Abbott closed its $400 million buyout of Visiogen Inc. and its intraocular lens technology.
It’s the second vision care acquisitions this year for the Chicago-based medical devices giant, which dropped a whopping $2.8 billion on Advanced Medical Optics in February.
Abbott said its latest deal gives it Irvine, Calif.-based Visiogen’s Synchrony accommodating intraocular lens, an implant designed to correct presbyopia in cataract patients.
The device is undergoing clinical trials in the U.S. and has already landed CE Mark approval in the European Union, where it’s been on the market since January. The U.S. Food & Drug Administration is also reviewing the device.